William Windham, MD
Urology · Starkville, MSNPI 1861832289
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,262 of the $6,849 with a category attached, or 62.2%. 33 manufacturers reported payments, led by Boston Scientific at 35.4% of the total. Reporting peaked in 2022 at $2,771 and has fallen 87.0% since, to $360 in 2025.
Across 132 payments — averaging $51.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Neotract Inc.$1K
- Teleflex LLC$561
- EDAP Technomed Inc$378
- Dendreon Pharmaceuticals LLC$276
- Astellas Pharma US Inc$258
- plus $2K from 27 others
What the payments were for
- Travel & lodging$2,43736%
- Food & beverage$4,26262%
- Education$1502%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 13 | $2,424 |
| Neotract Inc. | 10 | $1,361 |
| Teleflex LLC | 7 | $561 |
| EDAP Technomed Inc | 3 | $378 |
| Dendreon Pharmaceuticals LLC | 9 | $276 |
| Astellas Pharma US Inc | 14 | $258 |
| AbbVie | 18 | $222 |
| Johnson & Johnson | 6 | $185 |
| Medtronic(2 entities) | 4 | $163 |
| Myriad Genetic Laboratories, Inc. | 5 | $136 |
| Sumitomo Pharma America, Inc. | 2 | $84 |
| Axonics, Inc. | 3 | $66 |
| Endo Pharmaceuticals Inc. | 3 | $62 |
| Pfizer | 4 | $60 |
| Procept Biorobotics Corporation | 2 | $57 |
| Cook Medical LLC | 1 | $50 |
| Coloplast | 3 | $47 |
| Hollister Incorporated | 3 | $47 |
| Endo USA, Inc. | 2 | $43 |
| Verity Pharmaceuticals Inc. | 2 | $42 |
| Blue Earth Diagnostics | 2 | $36 |
| AstraZeneca | 1 | $35 |
| Merck | 2 | $35 |
| Urogen Pharma, Inc. | 2 | $29 |
| Bayer | 2 | $29 |
| Immunitybio, Inc. | 1 | $28 |
| Novartis | 1 | $24 |
| Pacira Therapeutics, Inc. | 1 | $21 |
| Travere Therapeutics, Inc. | 2 | $20 |
| Tolmar Pharmaceuticals, Inc. | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
| Photocure Inc | 1 | $18 |
| Olympus America Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TACTRA$1,666
- UroLift$1,203
- AdVance XP$421
- UroLift System$236
- AMS$115
- Erleada$109
How this compares
$6,849 in reported general payments places this provider in the 75th percentile of 94 urology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 16 | $220,719 |
| GemtesaVibegron | 65 | $46,363 |
| MyrbetriqMirabegron | 65 | $46,064 |
| Tamsulosin Hcl | 1,308 | $16,467 |
| Testosterone Cypionate | 296 | $14,147 |
| Finasteride | 764 | $9,774 |
| Solifenacin Succinate | 154 | $7,954 |
| Dutasteride | 99 | $3,722 |
| Oxybutynin Chloride ErOxybutynin Chloride | 141 | $3,441 |
| Tolterodine Tartrate ErTolterodine Tartrate | 37 | $3,326 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 56 | $2,725 |
| Potassium Citrate ErPotassium Citrate | 32 | $2,343 |
| Estradiol | 22 | $1,594 |
| Anastrozole | 395 | $1,419 |
| Silodosin | 12 | $1,190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $258 | $266,78381 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $84 | $46,36365 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 94 urology providers in Mississippi.
Other urology in Starkville
- Sarah RentropStarkville$6K
- Sean DouglasHattiesburg$40K
- Robert HollabaughSouthaven$17K
- Kristopher WhiteheadTupelo$17K
- Harold BlalockJackson$15K
- Jon PoseyTupelo$13K
- Paul FarabaughTupelo$13K
- Clarance FarmerTupelo$12K
- Patrick DailyJackson$12K
- Kaitlen SchexnayderHattiesburg$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.